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Abstract 
Heart failure is a growing epidemic that will add significant monetary and human costs to an 
already overtaxed health-care system. Though promising new medications have recently been 
approved, this complex condition is largely preventable through aggressive risk factor 
modification, with diet being shown to have a greater effect than exercise. An underrated 
component of a healthy diet is the simple addition of nuts – the anti-inflammatory fatty acids, 
healthy proteins, and general availability have been shown to improve survival and reduce the 
primary risk factors contributing to heart failure, making the addition of nuts and legumes to the 
diet an attractive, cost-effective tool to promote cardiovascular well-being. 
Keywords 
heart failure, diet, nuts, legumes, fatty acids, risk factor modification 
Introduction 
Heart failure, defined as a “complex clinical syndrome that results from any structural or 
functional impairment of ventricular filling or ejection of blood”1, is the most common reason 
for hospitalization in patients over 65 years of age2 and has reached epidemic proportions. In 
2013, the prevalence was estimated to be 5.8 million in the US and 23 million worldwide3, with 
an incidence of 870,000 new cases in the US in 20154 and a 5 year mortality of 50%.5 Heart 
failure increases in incidence with age, affecting nearly 20 per 1000 persons aged 65-69 and 
rising sharply to more than 80 per 1000 among those older than 856 – this is particularly 
concerning given that 20% of Americans are expected to be over age 65 by 2050.7 In 2012 as 
part of the Affordable Care Act, the Readmission Reduction Program was put into effect, 
imposing financial penalties on hospital systems with higher than average 30 day readmission 
rates for various conditions – this has helped to decrease the 30 day readmission for heart failure 
from 25% in 2009 to approximately 21.9% in 2016.8 However, the more than $30 billion cost of 
treating heart failure – including hospitalizations, medications, and lost wages – is only expected 
to rise.9 In fact, with an expected increase in heart failure prevalence to more than 8 million in 
the US, the total cost is projected to more than double, from over $30 billion currently to $70 
billion by 2030.10 
Risk Factors 
Heart failure is defined by the ACC/AHA stages (Stage A = risk factors, Stage B = structural 
heart disease, Stage C and D = structural heart disease with previous or current symptoms) and 
the NYHA functional classes (Class I = no functional limitations, Class II = slight limitation; 
ordinary physical activity results in symptoms, Class III = marked limitation in physical activity 
but comfortable at rest, Class IV = symptoms at rest).1 Hypertension and coronary artery disease 
have been recognized as the most important risk factors since the early 1990s11, with others 
including valvular heart disease, physical inactivity, male gender, lower levels of education, 
cigarette smoking, overweight, and diabetes.12 Roughly half of heart failure cases are considered 
HFrEF (heart failure with reduced ejection fraction), with EF<40% - mostly due to myocardial 
infarction by way of coronary artery disease – with the other half referred to as heart HFpEF  
(heart failure with preserved ejection fraction), with EF>50%1, a heterogeneous umbrella term 
under which are subsumed various disparate pathologies. Though there is considerable overlap 
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between the two entities, particularly with regard to symptomatology and diastolic dysfunction, 
risk factors for HFpEF lean towards older age, female gender, atrial fibrillation, and 
hyperlipidemia (in addition to obesity, CAD, and DM), with hypertension being the greatest risk 
factor.1 Dyslipidemia has been recognized as a major risk factor for CAD and therefore HFrEF 
since evaluation of the original Framingham data13 though its role in HFpEF is thought to be 
more complex, contributing to an inflammatory milieu in the setting of systemic and endothelial 
inflammation wrought by hypertension, diabetes, and obesity, the resultant reduction in nitric 
oxide bioavailability and molecular derangements, all culminating in ventricular stiffness.14 
Pharmacological Treatment 
Current nonsurgical treatment for stage B and C HFrEF, including evidence-based beta blockade, 
angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), 
aldosterone receptor inhibitors, and diuresis for symptoms1 have recently been updated to 
include combination angiotensin receptor blockers and neprilysin inhibition (ARNI) and 
ivabradine, for further rate control.15 Pharmacological recommendations for HFpEF are much 
less robust, limited to blood pressure control, diuresis for symptomatic relief, and a potential role 
for ARBs in reducing hospitalizations.1 To date, unlike HFrEF, there are no HFpEF-specific 
medications to improve mortality.  Thus, a greater focus is being placed not only on the 
prevention of heart failure in general, but on the amelioration of contributing conditions. In heart 
failure stage A (patients at risk but without structural disease or symptoms), treatment of 
hypertension and lipid disorders receives an IA recommendation, with treatment of obesity and 
diabetes receiving an IC recommendation.1 
Lifestyle Modification 
Therapeutic lifestyle interventions are the cornerstone of treatment for the primary risk factors 
for heart failure – hypertension, type 2 diabetes, obesity, and dyslipiedemia.16-19 In one study, 
systolic and diastolic blood pressure improved by 20 and 8 points respectively, through diet and 
exercise20, and in another, dietary changes alone were found to be an effective treatment for 
hypertension.21 Diet and exercise were associated with a 42% reduction in the risk of developing 
type 2 diabetes22, and a 50% remission in diabetes after 6 years.23 One meta-analysis reported a 
5.8-25% increase in HDL with varying results on LDL due to diet and exercise24, while another 
reported a maximum improvement in LDL of 18 points ( mean  of 8.5 points) due to diet alone, 
that increased to a maximum of 21.7 point (mean of 11) when exercise was added.25 It goes 
without saying that diet and exercise are the mainstays of treatment for obesity. It also goes 
without saying that aggressive lifestyle management of the primary risk factors for heart failure 
would reduce its incidence, prevalence, morbidity, and mortality – particularly for patients of 
lower socioeconomic status, who not only have higher heart failure readmissions, but have 
higher mortality.26  
Physical Activity 
The Physical Activity Guidelines for Americans recommend moderately intense aerobic activity 
for at least 2.5 hours weekly, vigorous aerobic activity for 1 hour and 15 minutes (or a 
combination) in addition to strength training27, and the ACC/AHA Guidelines on Lifestyle 
Management to Reduce Cardiovascular Risk recommend 3-4 weekly 40 minute sessions of 
moderate-vigorous activity.28 While it is estimated that 18% of Americans over age 18 meet the 
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aerobic and strength training recommendation, nearly 50% of US adults meet the aerobic 
recommendations.29 However, with nearly 33.5% of adults being hypertensive, 12.6% with 
diabetes, 12.1% with high serum cholesterol30, and nearly33% obese31, it would be overly 
simplistic to assume that these numbers could be brought to zero by perfect compliance with the 
exercise recommendations. Many of the patients who would benefit the most are unable to 
exercise due to the comorbidities of their illnesses. Nevertheless, diet carries the lion’s share of 
weight loss – a meta-analysis concluded that on average, study participants were able to reduce 
their weight by 10.7kg through diet alone, 2.9kg though exercise alone, and 11kg with diet and 
exercise.32 
Diet 
Decades of research have produced an abundance of information linking isolated macronutrients 
and eating patterns to various health outcomes and associated serum markers. The western diet is 
characterized by higher intake of processed grains, eggs, salt, high fat dairy, red and processed 
meats, sweets, white potatoes, French fries, and sugar sweetened beverages33 and has been 
associated with CAD, obesity, hypertension, hyperlipidemia and type 2 diabetes34 by way of 
systemic inflammatory marker such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, and 
high-sensitivity C-reactive protein (hsCRP).35 Markers of endothelial dysfunction – E-selectin, 
soluble intercellular adhesion molecule (sICAM)-1 and soluble vascular cell adhesion molecule 
(sVCAM)-1 – are also associated with the western diet.36  
In contrast, various dietary patterns have been consistently associated with lower levels of 
inflammatory markers and improved health outcomes. The National Institute of Health 
sponsored Dietary Approaches to Stop Hypertension (DASH) diet is based on 2000 calories 
daily and recommends 6-8 daily servings of grains, 6 or fewer servings of meats, fish, and 
poultry, 4-5 servings of fruits, 4-5 servings of vegetables, 2-3 servings of low fat or fat free 
dairy, 2-3 servings of fats and oils, 4-5 weekly servings of nuts, seeds, dry beans, and peas, and 5 
or fewer weekly servings of sweets. Importantly, sodium is restricted to 2300 mg at most.37 A 
meta-analysis showed the DASH diet to contribute a 20% reduction in the risk of cardiovascular 
disease, 19% reduction in risk of coronary heart disease, 19% reduction in risk of stroke, and a 
29% reduction in risk of heart failure.38 
The Mediterranean diet is characterized by the historical dietary pattern in the Mediterranean 
region and includes daily consumption of whole grains, vegetables, fruits, low fat dairy, 
monounsaturated fatty acids in the form of olive oil (the primary source for α-linolenic acid / 
ALA, an essential polyunsaturated fatty acid (PUFA), and moderate daily consumption of wine 
with meals, with weekly consumption of fish, poultry, nuts and legumes, and minimization of red 
meat.39 It has been associated with a 9% reduction in cardiovascular disease mortality and a 9% 
reduction in overall mortality40, a -0.69 log hazard ratio for metabolic syndrome (in addition to 
improving waist circumference, HDL, and BP)39, and a 19% reduction in risk of diabetes.41 
Vegetarian diets, which eschew meat, fish, poultry, eggs, and dairy, have been determined by the 
American Dietetic Association to be healthful, complete, and useful in the treatment and 
prevention of disease in all stages of life (including pregnancy and infancy, and at all energy 
levels. Compared with nonvegetarians, vegetarians have lower cholesterol levels, BMI, 
cholesterol, rates of diabetes and cancer, and rates of death from CAD.42 Two case series showed 
that vegetarian diets are associated with improvement in angiographically determined coronary 
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artery disease.43,44 Vegetarians have been shown to have significantly lower cholesterol levels 
than nonvegetarians45,46, as well as up to 24% lower risk of death from coronary artery disease.47 
Dietary Fatty Acids 
The association of fatty acids and health, particularly pertaining to coronary artery disease and 
heart failure, cannot be understated, given their association with serum inflammatory markers.35  
In one study, dietary fatty acids strongly correlated with levels of CRP, total cholesterol, 
apolipoprotein B, and LDL, and PUFA levels were inversely related to CRP – the highest 
quartile of saturated fatty acid (SFA) intake was associated with a twofold greater risk of CHD, 
and the opposite difference was seen with PUFA (but not MUFA).48 A study of compensated 
HFrEF patients on optimal medical therapy revealed higher TNF-α levels and lower event free 
survival in patients with higher intake of SFA and trans fatty acids (TFA), while patients who 
consumed diets higher in omega-3 and other polyunsaturated fats had lower levels of TNF 
receptors.49 Data from the Harvard Nurses’ Health Study revealed that (TFA) intake was 
associated with elevated levels of soluble TNF receptors 1 and 2 – also, TFA intake was 
associated with CRP in women with elevated BMI.50 TFA levels positively correlate with 
elevated LDL, lower HDL, elevated IL-6, CRP, and TNF-α, even when compared to SFA. When 
2% of energy from SFA, carbohydrate, MUFA, and PUFA were isocalorically replaced with 
TFA, risk of myocardial infarction or death due to cardiovascular causes increased 20, 24, 27, 
and 32%, respectively.51 Specifically, omega-3 (n-3 polyunsaturated) fatty acids are associated 
with lower levels of inflammatory markers, and may even have anti-arrhythmic effects, thought 
to be due to their effect on cardiac membranes.52 The N-3 fatty acids eicosapentaenoic acid 
(EPA) and docosapentaenoic acid (DPA) are inversely associated with levels of CRP in healthy 
subjects53, and  EPA and docosahexaenoic acid (DHA) are inversely associated with levels of 
CRP and IL-6 in patients with stable coronary artery disease.54 The association of fatty acids 
with cardiovascular health is further complicated by susceptibility to oxidative damage. Diets 
rich in MUFA showed increased resistance to oxidation, whereas PUFA are more prone to 
oxidation – a quality which extends to the PUFA moieties of LDL.55,56 Oxidized LDL is highly 
associated with coronary artery stenosis57, negatively correlates with ejection fraction, and is a 
predictor of mortality in heart failure.58 
Dietary Nut Intake 
Nuts are one of the most readily available sources of beneficial fatty acids, and ample research 
exists showing their association with health and longevity. A diet including nut consumption has 
been shown to be associated with deceased risk of obesity and weight gain59, and higher levels of 
nut intake were associated with weight loss.60,61 Walnuts - rich in antioxidants and ALA (n-3 
fatty acid) -improved endothelial function as evidenced by reduction in sICAM-1 in 
hyperlipidemic patients 62 and flow mediated dilatation in diabetics.63 Improvement in 
endothelium dependent vasodilation may be due to the presence of arginine in nuts, and its role 
in nitric oxide biosynthesis.64 Diets including nuts have been found to improve lipid profiles65-69, 
decrease risk of coronary heart disease70-71,and reduce all-cause mortality.72-75 A 2015 review 
found that nut intake was inversely related to mortality among a cohort of over 206,000 African 
American and Chinese men and women, many from a lower socio-economic status. The increase 
in survival in all ethnic groups was due to improvement in ischemic heart disease associated with 
peanut intake – peanuts are ubiquitous and inexpensive, and thus were determined to be an ideal 
dietary option to reduce cardiovascular risk.76 
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Conclusion 
As stated above, heart failure is a fast-growing medical and financial crisis. While new therapies 
will inevitably be developed, the focus on prevention and lifestyle modifications cannot be 
overstated. Small nutritional changes may be associated with greater compliance than large 
dietary overhaul, and can lay the groundwork for sustainable improvement. The incorporation of 
nuts into a heart-healthy diet is one such change that, though it may be small, has undeniably 
significant health benefits, and may reduce heart failure incidence, prevalence, morbidity, and 
mortality. 
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